Canada markets closed

Lophos Holdings Inc. (MESC.CN)

Canadian Sec - Canadian Sec Real Time Price. Currency in CAD
Add to watchlist
0.05000.0000 (0.00%)
At close: 12:44PM EDT
Full screen
Previous Close0.0500
Open0.0000
Bid0.0000 x N/A
Ask0.0000 x N/A
Day's Range0.0500 - 0.0500
52 Week Range0.0300 - 0.3000
Volume0
Avg. Volume93,375
Market Cap4.293M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.0200
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Newsfile

    Lophos Pharmaceuticals Corp. Receives Traditional Blessing for Napanee Site in Honor of Indigenous Heritage

    Napanee, Ontario--(Newsfile Corp. - May 15, 2024) - Lophos Holdings Inc. (CSE: MESC) ("Lophos" or the "Company") proudly announces the traditional blessing of its Napanee site, paying homage to the indigenous heritage of its founders and sanctifying the grounds for the cultivation of Lophophora williamsii (peyote) moving forward.The ceremony, led by esteemed elders, holds deep significance for Lophos Pharmaceuticals Corp., a subsidiary wholly-owned by Lophos Holdings Inc. This blessing is a test

  • GlobeNewswire

    Lophos Pharmaceuticals Corp. Enters Into Letter of Intent to Acquire the Assets of Magicactus.com

    NAPANEE, Ontario, May 06, 2024 (GLOBE NEWSWIRE) -- Lophos Holdings Inc. ("Lophos", or the "Company") (CSE:MESC) is pleased to announce that its wholly-owned subsidiary, Lophos Pharmaceuticals Corp. (“Lophos Pharma”) - a biosciences company specializing in the cultivation, research, and sale of Lophophora williamsii (peyote), announced today that it has entered into a letter of intent to acquire the cactus cultivation business of Magicactus.com. Under the terms of the letter of intent, Lophos Pha

  • GlobeNewswire

    Lophos Pharmaceuticals Corp. Commences Peyote Research Protocol

    NAPANEE, Ontario, May 02, 2024 (GLOBE NEWSWIRE) -- Lophos Holdings Inc. ("Lophos", or the "Company") (CSE:MESC) is pleased to announce the official commencement of its first research protocol under its wholly-owned subsidiary, Lophos Pharmaceuticals Corp. The protocol, centered on the cultivation of Lophophora williamsii (Peyote), marks a significant milestone in Lophos' dedication to advancing sustainable indoor cultivation practices for this endangered species. The research protocol, developed